Gradually increased <scp>G</scp>olgi protein 73 expression in the progression of benign liver diseases to precancerous lesions and hepatocellular carcinoma correlates with prognosis of patients

Shan, Shigang; Gao, Yingtang; Xu, Yanjie; Huang, Yong; Zhang, Qin; Zhai, Daokuan; Li, Jianbiao; Wang, Fengmei; Jing, Xiang; Zhi, Du; Wang, Yijun

doi:10.1111/hepr.12078

Cited by 20 publications

(27 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although the sGP73 levels in HCC were similar to those in liver cirrhosis in the present study, a number of studies reported higher sGP73 levels in HCC than in liver cirrhosis (19)(20)(21), or higher sGP73 levels in liver cirrhosis than in HCC (15,25). This discrepancy may be partly due to the heterogeneity of the disease stage of patients with HCC or liver cirrhosis among different studies.…”

Section: Discussioncontrasting

confidence: 54%

“…Few studies have investigated the association of sGP73 with the clinicopathological characteristics and prognosis of HCC (15,21). In the present study, it was identified that high levels of sGP73 were associated with aggressive tumor behavior and poor DFS and OS times, and that sGP73 was an independent negative prognostic factor Figure 4.…”

Section: Discussionmentioning

confidence: 63%

“…Upregulated hepatocyte expression of GP73 has previously been reported in the liver tissues not only of patients with HCC, but also of those with other liver disease, including liver cirrhosis (12), chronic hepatitis, hepatic atypical hyperplasia (15), liver cell adenoma, and focal nodular hyperplasia (23). High tissue levels of GP73 have also been observed in adenocarcinomas of the prostate, colon and breast, in renal cell cancer (26), and in bile duct carcinoma (23), suggesting that GP73 is not a HCC-specific biomarker.…”

Section: Discussionmentioning

confidence: 94%

“…By contrast, enzyme-linked immunosorbent assay (ELISA) is quantitative and convenient. Although a number of studies have demonstrated higher levels of sGP73 measured by ELISA in HCC than in liver cirrhosis (19)(20)(21), no significant difference in sGP73 concentrations between HCC and cirrhosis groups was identified by other studies (22)(23)(24), and in a number of studies, the sGP73 level was even lower in HCC than in liver cirrhosis (15,25). Considering the small sample size of these studies, further evaluation of ELISA-measured sGP73 in large-scale studies is required to clarify its diagnostic value in HCC.…”

Section: Serum Golgi Protein 73 Is a Prognostic Rather Than Diagnostimentioning

confidence: 87%

“…Aberrant expression of GP73 in hepatocytes is present in chronic liver disease, including viral and non-viral hepatitis, liver cirrhosis and HCC (12)(13)(14). Additionally, gradually increasing GP73 expression levels in tissue have been observed throughout the progression from normal liver and chronic hepatitis to HCC (15). Importantly, the C-terminal ectodomain of GP73 can be released into the circulation (16).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Serum Golgi protein 73 is a prognostic rather than diagnostic marker in hepatocellular carcinoma

Dong

Chen

et al. 2017

Oncol Lett

View full text Add to dashboard Cite

Abstract. Serum Golgi protein 73 (sGP73) is a candidate diagnostic biomarker for hepatocellular carcinoma (HCC). However, current evidence of its diagnostic value is conflicting, primarily due to the small sample sizes of previous studies, and its prognostic role in HCC also remains unclear. In the present study, sGP73 levels in 462 patients with HCC, 186 patients with liver cirrhosis, and 83 healthy controls were evaluated using ELISA, and it was identified that the median sGP73 levels were significantly higher in the HCC (18.7 ng/ml) and liver cirrhosis (18.5 ng/ml) patients than in the healthy controls (0 ng/ml; both P<0.001); however, the levels did not significantly differ between the HCC and liver cirrhosis groups (P=0.632). sGP73 had an inferior sensitivity and specificity for HCC diagnosis (27.79 and 77.96%, respectively) compared with α-fetoprotein (57.36 and 90.96%, respectively; P<0.001). In the HCC group, a high level of sGP73 was associated with aggressive clinicopathological features and independently predicted poor overall survival (OS) time (P<0.001). Additionally, in patients with resectable HCC, a high level of sGP73 was associated with significantly decreased disease-free survival (P<0.001) and OS (P=0.039) times compared with a low level of sGP73. This study demonstrated that sGP73 is unsuitable as a diagnostic marker for the early detection of HCC; however, it is an independent negative prognostic marker, providing a novel risk stratification factor and a potential therapeutic molecular target for HCC.

show abstract

Section: Discussioncontrasting

confidence: 54%

Section: Discussionmentioning

confidence: 63%

Section: Discussionmentioning

confidence: 94%

Section: Serum Golgi Protein 73 Is a Prognostic Rather Than Diagnostimentioning

confidence: 87%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Serum Golgi protein 73 is a prognostic rather than diagnostic marker in hepatocellular carcinoma

Dong

Chen

et al. 2017

Oncol Lett

View full text Add to dashboard Cite

show abstract

Possible roles of Golgi protein-73 in liver diseases

Liu

et al. 2022

Annals of Hepatology

View full text Add to dashboard Cite

Golgi protein 73, hepatocellular carcinoma and other types of cancers

Wang

Wan

2020

Liver Research

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common malignant tumors with a low survival rate. The identification of mechanisms underlying the development of HCC helps uncover cellular and molecular targets for the diagnosis, prevention, and treatment of HCC. Golgi protein 73 (GP73) level is upregulated in HCC patients and potentially can be a therapeutic target. Despite many studies devoted to GP73 as a marker for HCC early diagnosis, there is little discussion about the function of GP73 in HCC tumorigenesis. Given the poor response to currently available HCC therapies, a better understanding of the role of GP73 in HCC may provide a new therapeutic target for HCC. The current paper summarizes the role of GP73 as a diagnostic marker as well as its roles in liver carcinogenesis. Its roles in other types of cancer are also discussed.

show abstract

Gradually increased Golgi protein 73 expression in the progression of benign liver diseases to precancerous lesions and hepatocellular carcinoma correlates with prognosis of patients

Abstract: GP73 expression pattern suggests that the regulatory mechanism of GP73 is related to the progression of chronic liver diseases. Furthermore, a high level of tGP73 is a favorable prognostic factor for HCC.

Cited by 20 publications

References 29 publications

Serum Golgi protein 73 is a prognostic rather than diagnostic marker in hepatocellular carcinoma

Serum Golgi protein 73 is a prognostic rather than diagnostic marker in hepatocellular carcinoma

Possible roles of Golgi protein-73 in liver diseases

Golgi protein 73, hepatocellular carcinoma and other types of cancers

Contact Info

Product

Resources

About